A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Novo Nordisk A/S
- Study ID
- NCT07564414
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cagrisema — DRUGCagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.
- Semaglutide — DRUGSemaglutide will be administered subcutaneously.
Study Details
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
Key Dates
- Start date
- May 21, 2026
- Status verified
- May 2026
- Primary completion
- Feb 23, 2028
- Completion
- Apr 19, 2028
Study Design
- Enrollment
- 2,500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cagrisema - dose level 1Participants will receive CagriSema at dose level 1 once weekly subcutaneously during the treatment period for 72 weeks.
- Active Comparator: Cagrisema - dose level 2Participants will receive CagriSema at dose level 2 once weekly subcutaneously during the treatment period for 72 weeks.
- Active Comparator: SemaglutideParticipants will receive Semaglutide once weekly subcutaneously during the treatment period for 72 weeks.
Primary Outcome Measure
Relative change in body weight [ Time Frame: From randomisation (week 0) to end of treatment (week 72) ]
Central Contacts
- Novo Nordisk(+1) 866-867-7178
Locations (99)
Find similar trials in Birmingham, AL
By condition
By specialty
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia